Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rande Is who wrote (31710)	8/10/2000 11:01:49 AM
From: Pied Piper	Respond to of 57584

NATS earnings out. Doesn't look bad to me but the market is less than enthusiastic, as usual. biz.yahoo.com Piper

To: Rande Is who wrote (31710)	8/10/2000 11:01:56 AM
From: GREENLAW4-7	Read Replies (1) \| Respond to of 57584

PROBLEMS with market; oil at 31bbl, bio-tech's breaking down, chips being sold into amats earnings, and dell may actually dissapoint!! Short quickly drillers!!

To: Rande Is who wrote (31710)	8/10/2000 11:02:24 AM
From: Baton	Respond to of 57584

This may give a boost to the bio's. Baton biz.yahoo.com IBC USA Conferences The Genome: What Are the Key Business Implications? The World Trade Center and Seaport Hotel, Boston, MA. August 14-17, 2000 www.drugdisc.com BOSTON, Aug. 10 /PRNewswire/ -- More than 4,000 scientists, researchers and business executives from the biotechnology, genomics and pharmaceutical industries will convene August 14 - 17 at the World Trade Center in Boston for the largest ever global industry-focused drug discovery meeting - Drug Discovery Technology 2000. ``Both the development and correct deployment of new technologies that can leverage the huge amount of information coming from the Human Genome are crucial to increasing productivity of the industry,'' comments Michael R. Pavia, PhD, Chief Technology Officer of Millennium Pharmaceuticals, and a member of the Drug Discovery Technology 2000 Scientific Advisory Committee. ``DDT 2000 represents the premier forum for presenting and discussing these technology advances.'' The program will include: J. Craig Venter, PhD President, Celera Genomics Group (NYSE: CRA - news) Frank Douglas, MD, PhD Head of Drug Innovation & Approval, Aventis Pharmaceuticals, the pharmaceutical company of Aventis S.A. (NYSE: AVE - news) Steven V. Ley, FRS Professor, Organic Chemistry, University of Cambridge, UK Elliott Sigal, MD, PhD Senior Vice President, Bristol-Myers Squibb (NYSE: BMY - news) Steven H Holtzman, PhD Chief Business Officer, Millennium Pharmaceuticals (Nasdaq: MLNM - news) Press Briefings scheduled to take place at Drug Discovery Technology 2000: TUESDAY